Post by Philipp Staber

When sample material is limited — as is the case for most clinical biopsy workflows — the choice of profiling technology matters. Work from Tea Pemovska, PhD and exalt #ASH2025 with single-cell drug profiling, consistently demonstrates that automated flow cytometry outperforms automated imaging when precious patient material is scarce. Lukas Kazianka et al. Hemasphere. 2025. https://lnkd.in/djKiv-ej Why? 🔹 Higher sensitivity at low cell numbers 🔹 Robust single-cell resolution without relying on large imaging fields 🔹 Faster, more reproducible quantification of drug responses across heterogeneous cell populations As personalized medicine moves toward smaller, earlier, and less invasive biopsies, technologies that deliver high-quality data from minimal input will define the next generation of functional testing.